vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $395.6M, roughly 1.8× Dolby Laboratories, Inc.). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs 19.1%, a 4.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 7.1%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 13.9%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DLB vs MEDP — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $708.5M |
| Net Profit | $94.9M | $135.1M |
| Gross Margin | 88.7% | — |
| Operating Margin | 28.5% | 21.6% |
| Net Margin | 24.0% | 19.1% |
| Revenue YoY | 7.1% | 32.0% |
| Net Profit YoY | 3.4% | 15.5% |
| EPS (diluted) | $0.99 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $708.5M | ||
| Q3 25 | $307.0M | $659.9M | ||
| Q2 25 | $315.5M | $603.3M | ||
| Q1 25 | $369.6M | $558.6M | ||
| Q4 24 | $357.0M | $536.6M | ||
| Q3 24 | $304.8M | $533.3M |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $135.1M | ||
| Q3 25 | $49.3M | $111.1M | ||
| Q2 25 | $46.1M | $90.3M | ||
| Q1 25 | $91.8M | $114.6M | ||
| Q4 24 | $67.8M | $117.0M | ||
| Q3 24 | $58.6M | $96.4M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | — | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 86.1% | — | ||
| Q1 25 | 90.3% | — | ||
| Q4 24 | 88.6% | — | ||
| Q3 24 | 88.8% | — |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 21.6% | ||
| Q3 25 | 9.7% | 21.5% | ||
| Q2 25 | 15.1% | 20.9% | ||
| Q1 25 | 29.2% | 20.3% | ||
| Q4 24 | 22.4% | 23.4% | ||
| Q3 24 | 15.2% | 21.1% |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | 19.1% | ||
| Q3 25 | 16.1% | 16.8% | ||
| Q2 25 | 14.6% | 15.0% | ||
| Q1 25 | 24.8% | 20.5% | ||
| Q4 24 | 19.0% | 21.8% | ||
| Q3 24 | 19.2% | 18.1% |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $4.65 | ||
| Q3 25 | $0.50 | $3.86 | ||
| Q2 25 | $0.48 | $3.10 | ||
| Q1 25 | $0.94 | $3.67 | ||
| Q4 24 | $0.70 | $3.67 | ||
| Q3 24 | $0.59 | $3.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $459.1M |
| Total Assets | $3.2B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $497.0M | ||
| Q3 25 | $702.6M | $285.4M | ||
| Q2 25 | $699.3M | $46.3M | ||
| Q1 25 | $626.6M | $441.4M | ||
| Q4 24 | $520.8M | $669.4M | ||
| Q3 24 | $482.0M | $656.9M |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $459.1M | ||
| Q3 25 | $2.6B | $293.6M | ||
| Q2 25 | $2.6B | $172.4M | ||
| Q1 25 | $2.6B | $593.6M | ||
| Q4 24 | $2.5B | $825.5M | ||
| Q3 24 | $2.5B | $881.4M |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $2.0B | ||
| Q3 25 | $3.2B | $1.8B | ||
| Q2 25 | $3.2B | $1.6B | ||
| Q1 25 | $3.2B | $1.9B | ||
| Q4 24 | $3.2B | $2.1B | ||
| Q3 24 | $3.1B | $2.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | 1.55× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $192.7M | ||
| Q3 25 | $472.2M | $246.2M | ||
| Q2 25 | $67.7M | $148.5M | ||
| Q1 25 | $174.9M | $125.8M | ||
| Q4 24 | $106.8M | $190.7M | ||
| Q3 24 | $327.3M | $149.1M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $188.1M | ||
| Q3 25 | $435.9M | $235.5M | ||
| Q2 25 | $61.3M | $142.4M | ||
| Q1 25 | $168.0M | $115.8M | ||
| Q4 24 | $100.0M | $183.0M | ||
| Q3 24 | $297.2M | $138.5M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 26.6% | ||
| Q3 25 | 142.0% | 35.7% | ||
| Q2 25 | 19.4% | 23.6% | ||
| Q1 25 | 45.5% | 20.7% | ||
| Q4 24 | 28.0% | 34.1% | ||
| Q3 24 | 97.5% | 26.0% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 0.6% | ||
| Q3 25 | 11.8% | 1.6% | ||
| Q2 25 | 2.0% | 1.0% | ||
| Q1 25 | 1.9% | 1.8% | ||
| Q4 24 | 1.9% | 1.4% | ||
| Q3 24 | 9.8% | 2.0% |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | 1.43× | ||
| Q3 25 | 9.57× | 2.22× | ||
| Q2 25 | 1.47× | 1.65× | ||
| Q1 25 | 1.91× | 1.10× | ||
| Q4 24 | 1.57× | 1.63× | ||
| Q3 24 | 5.59× | 1.55× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
